Office of Public Affairs

Office of Public Affairs

EmailEmail    |   Bookmark Page Bookmark  |   RSS Feeds RSS  |   Print Page Print  
Share |

Research featured on cover of Arteriosclerosis, Thrombosis and Vascular Biology

June 27, 2013 College News - Roy Silverstein, MD, and colleagues at the Cleveland Clinic Lerner Research Institute, are conducting research to identify how two proteins (thrombospondin-1 TSR and CD36 CLESH) that inhibit angiogenesis interact on a molecular level. This work, including a cover picture of a molecular model of the interaction, was published online ahead of the July 2013 issue of Arteriosclerosis, Thrombosis and Vascular Biology.

Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels, and it has shown to play a role in human disease. In their study, Molecular basis of anti-angiogenic thrombospondin-1 type 1 repeat domain interactions with CD36, Dr. Silverstein and the team explored what molecular processes impact how the two proteins interact. Understanding of this can lead to better treatments for cardiovascular diseases.

Team members include Philip A. Klenotic, Richard C. Page, Joseph Amick and Saurav Misra, from the Cleveland Clinic Department of Molecular Cardiology; Wei Li, from the Cleveland Clinic Department of Cellular and Molecular Medicine; and Dr. Silverstein, the John and Linda Mellowes Professor and Chair of Medicine at MCW.

Molecular model depicting the interaction of thrombospondin-1 TSR2 domain with the CLESH domain of CD36. TSR2 residues that bind to the CD36-CLESH are colored according to identification by NMR (cyan), mutagenesis (green) or both (orange). CD36-CLESH is colored violet with TSR2-interacting residues shown as sticks.
© 2014 Medical College of Wisconsin
Page Updated 07/23/2013